• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

Malaria: New research promises to ease access to ASAQ and ASMQ treatment

Home > News

Malaria: New research promises to ease access to ASAQ and ASMQ treatment

29 Apr 2016
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Access to effective treatment is central in the fight against malaria. The recently published PREGACT study has shown that artemisinin-based combination therapies are effective in pregnant women with malaria in Africa, without the safety concerns of other treatment types. Another success for malaria treatment comes with the World Health Organization’s announcement that the fixed-dose combination of artesunate+mefloquine (ASMQ) shelf-life has been extended from two to three years, which will greatly help with storage and distribution. Both developments will have a positive impact on access to treatment for those who need it.

The PREGACT Study

Pregnant women are highly susceptible to malaria. Malaria infection during pregnancy may increase the risk of foetal loss and maternal death. Considering the harmful effects of malaria during pregnancy, it is vital to treat the disease adequately with effective medicines. WHO previously recommended for all women in malaria-endemic regions in Africa to receive intermittent preventative treatment with sulfadoxine-pyrimethamine, however this is challenged by widespread drug resistance in many regions.

In the PREGACT Study, a total of 3428 women from four sub-Saharan African countries (Burkina Faso, Ghana, Malawi, and Zambia) who were infected with P. falciparum malaria were randomized to one of the following four artemisinin-based combination therapies:

  1. Artemether-lumefantrine
  2. Amodiaquine-artesunate
  3. Dihydroartemisinin-piperaquine
  4. Mefloquine-artesunate

The trial was conducted as a multi-center, randomized, open-label trial. No significant difference in the rate of serious adverse events and in birth outcomes was found among the treatment groups.

The results showed a parasitological cure at day 63 and improved safety compared to the old treatment regimen.

WHO now recommends patients in the second and third trimester of pregnancy follow a three-day course of therapy. The short-acting artemisinin component reduces the number of parasites over the three days. The partner drug, which is longer-acting, helps to prevent new infections.

This study presents new and much needed evidence that artemisinin-based combination therapies are effective in pregnant women with malaria in Africa, without the safety concerns of sulfadoxine-pyrimethamine.

Extended shelf life for ASMQ

In March 2016, the WHO’s Prequalification Team announced an extended shelf-life from two to three years for the fixed-dose combination of artesunate+mefloquine (ASMQ). The change involves the extension from 24 months to 36 months when packed in Alu-Alu blister. Recommended as a first- or second-line treatment in South America and South-East Asia, the extended shelf life will help to reduce current supply-chain management issues in relation to warehousing and distribution.The longer shelf life applies to the prequalification status of both presentations of ASMQ (25/50mg and 100/200mg) developed by DNDi and Farmanguinhos (Brazil), and manufactured by Cipla.

Read, watch, share

Loading...
Doctor with patient in hospital setting
Press releases
5 Dec 2023

Cryptococcal meningitis: new report highlights slow uptake of guidelines shown to reduce deaths in Africa

Healthcare worker with patient
Press releases
3 Dec 2023

Germany’s Federal Ministry for Economic Cooperation and Development (BMZ) through KfW grants funding to fast-track access to medicines for poverty-related and neglected diseases

Laboratory staff working
News
3 Dec 2023

DNDi commits to cutting carbon emissions in half by 2030

People entering the Mycetoma Research Centre
Videos
23 Nov 2023

Mycetoma: Neglected but not Forgotten

Nurse caring for patient with a lesion on the feet
Press releases
23 Nov 2023

World’s first clinical trial for devastating fungal disease mycetoma shows efficacy of new, promising treatment

People standing under tents at the Run for Neglected Patients
News
23 Nov 2023

DNDi@20 charity run shines the spotlight on neglected diseases in Kenya

Viewpoints
20 Nov 2023

Africa Statistics Day: Statistics save lives, especially those of neglected patients

Africa Uncensored
Viewpoints
13 Nov 2023

Doenças negligenciadas ameaçam saúde pública global

Folha de S. Paulo
VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License